EP3906033A4 - Verfahren und materialien zur erhöhung des transkriptionsfaktor-eb-polypeptid-spiegels - Google Patents

Verfahren und materialien zur erhöhung des transkriptionsfaktor-eb-polypeptid-spiegels Download PDF

Info

Publication number
EP3906033A4
EP3906033A4 EP20736104.9A EP20736104A EP3906033A4 EP 3906033 A4 EP3906033 A4 EP 3906033A4 EP 20736104 A EP20736104 A EP 20736104A EP 3906033 A4 EP3906033 A4 EP 3906033A4
Authority
EP
European Patent Office
Prior art keywords
materials
methods
transcription factor
polypeptide levels
increasing transcription
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20736104.9A
Other languages
English (en)
French (fr)
Other versions
EP3906033A1 (de
Inventor
Beibei Chen
Toren Finkel
Yuan Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of EP3906033A1 publication Critical patent/EP3906033A1/de
Publication of EP3906033A4 publication Critical patent/EP3906033A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP20736104.9A 2019-01-03 2020-01-03 Verfahren und materialien zur erhöhung des transkriptionsfaktor-eb-polypeptid-spiegels Pending EP3906033A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788049P 2019-01-03 2019-01-03
US201962879374P 2019-07-26 2019-07-26
PCT/US2020/012268 WO2020142748A1 (en) 2019-01-03 2020-01-03 Methods and materials for increasing transcription factor eb polypeptide levels

Publications (2)

Publication Number Publication Date
EP3906033A1 EP3906033A1 (de) 2021-11-10
EP3906033A4 true EP3906033A4 (de) 2022-11-09

Family

ID=71406977

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20736104.9A Pending EP3906033A4 (de) 2019-01-03 2020-01-03 Verfahren und materialien zur erhöhung des transkriptionsfaktor-eb-polypeptid-spiegels

Country Status (12)

Country Link
US (1) US20220112218A1 (de)
EP (1) EP3906033A4 (de)
JP (1) JP7566753B2 (de)
KR (1) KR20210111787A (de)
CN (1) CN113316453A (de)
AU (1) AU2020204717A1 (de)
BR (1) BR112021012950A2 (de)
CA (1) CA3123902A1 (de)
IL (1) IL284403A (de)
MX (1) MX2021008152A (de)
SG (1) SG11202105685TA (de)
WO (1) WO2020142748A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CZ309449B6 (cs) * 2020-12-24 2023-01-25 Ústav experimentální botaniky AV ČR, v. v. i. Chinazolinové deriváty jako selektivní inhibitory cyklooxygenázy-1
CN113248518B (zh) * 2021-06-21 2022-03-25 山东大学 嘧啶哌嗪类衍生物及其制备方法与应用

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078166A1 (en) * 2000-09-15 2003-04-24 Robert Davies Pyrazole compounds useful as protein kinase inhibitors
WO2003057695A1 (en) * 2001-12-21 2003-07-17 Boehringer Ingelheim Pharmaceuticals, Inc. 1,6 naphthyridines useful as inhibitors of syk kinase
WO2004037814A1 (en) * 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
WO2004101513A2 (en) * 2003-05-08 2004-11-25 E.I. Dupont De Nemours And Company Preparation of (e)- and (z)-2-methyl-2-butenoic acids
WO2010015518A2 (de) * 2008-08-05 2010-02-11 Boehringer Ingelheim Interntional Gmbh 4-dimethylamino-phenyl-substituierte naphthyridine und ihre verwendung als arzneimittel
WO2010015520A1 (de) * 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituierte naphthyridine und ihre verwendung als arzneimittel
WO2011134971A1 (en) * 2010-04-29 2011-11-03 Glaxo Group Limited 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
WO2016081365A1 (en) * 2014-11-19 2016-05-26 Rush University Medical Center Compositions and methods for treating lysosomal disorders
WO2018089499A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
WO2018089433A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
WO2018089493A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PYRROLE mTORC INHIBITORS AND USES THEREOF
WO2018191146A1 (en) * 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
WO2004101512A2 (en) 2003-05-13 2004-11-25 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
WO2008157500A1 (en) * 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078166A1 (en) * 2000-09-15 2003-04-24 Robert Davies Pyrazole compounds useful as protein kinase inhibitors
WO2003057695A1 (en) * 2001-12-21 2003-07-17 Boehringer Ingelheim Pharmaceuticals, Inc. 1,6 naphthyridines useful as inhibitors of syk kinase
WO2004037814A1 (en) * 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
WO2004101513A2 (en) * 2003-05-08 2004-11-25 E.I. Dupont De Nemours And Company Preparation of (e)- and (z)-2-methyl-2-butenoic acids
WO2010015518A2 (de) * 2008-08-05 2010-02-11 Boehringer Ingelheim Interntional Gmbh 4-dimethylamino-phenyl-substituierte naphthyridine und ihre verwendung als arzneimittel
WO2010015520A1 (de) * 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituierte naphthyridine und ihre verwendung als arzneimittel
WO2011134971A1 (en) * 2010-04-29 2011-11-03 Glaxo Group Limited 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
WO2016081365A1 (en) * 2014-11-19 2016-05-26 Rush University Medical Center Compositions and methods for treating lysosomal disorders
WO2018089499A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
WO2018089433A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
WO2018089493A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PYRROLE mTORC INHIBITORS AND USES THEREOF
WO2018191146A1 (en) * 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOHNS B A ET AL: "1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 19, no. 6, 15 March 2009 (2009-03-15), pages 1807 - 1810, XP026005884, ISSN: 0960-894X, [retrieved on 20090130], DOI: 10.1016/J.BMCL.2009.01.089 *
JOHNS B A ET AL: "The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 19, no. 6, 15 March 2009 (2009-03-15), pages 1802 - 1806, XP026005883, ISSN: 0960-894X, [retrieved on 20090130], DOI: 10.1016/J.BMCL.2009.01.090 *

Also Published As

Publication number Publication date
CN113316453A (zh) 2021-08-27
WO2020142748A1 (en) 2020-07-09
IL284403A (en) 2021-08-31
MX2021008152A (es) 2021-10-13
JP7566753B2 (ja) 2024-10-15
CA3123902A1 (en) 2020-07-09
EP3906033A1 (de) 2021-11-10
BR112021012950A2 (pt) 2021-09-14
KR20210111787A (ko) 2021-09-13
SG11202105685TA (en) 2021-06-29
US20220112218A1 (en) 2022-04-14
AU2020204717A1 (en) 2021-06-10
JP2022516631A (ja) 2022-03-01

Similar Documents

Publication Publication Date Title
IL284403A (en) Methods and materials for increasing EB transcription factor polypeptide levels
EP3839034A4 (de) Kulturmaterial und verwendung desselben
EP4021928A4 (de) Modifiziertes n-810 und verfahren dafür
EP4006054A4 (de) Verfahren und zusammensetzung für anti-cd73-antikörper und varianten
EP4009777A4 (de) Transkriptionsfaktor nterf221 und verfahren zur verwendung davon
EP4026382A4 (de) Verfahren und vorrichtungen für sidelink-vorgänge
EP3976657A4 (de) Anti-trka-antikörper und verwendungen davon
EP3980004A4 (de) Tributyrinzusammensetzungen und verfahren dafür
EP3971225A4 (de) Polymerisierbare zusammensetzung für optisches material und verwendung davon
EP4049008A4 (de) Verfahren zum nachweis von fentanylanaloga und kits dafür
EP4069849A4 (de) Leberspezifischer promotor und verwendung davon
EP4081645A4 (de) Fermentationsverfahren und verwendungen davon
EP4007586A4 (de) Zellen zur verbesserten immuntherapie und deren verwendungen
EP3960731A4 (de) Thiolhaltige zusammensetzung für optisches material und polymerisierbare zusammensetzung für optisches material
EP4025585A4 (de) Modifizierte peptide und damit verbundene verwendungsverfahren
EP3605840A4 (de) Betriebsverstärker und steuerverfahren dafür
EP4007591A4 (de) Materialien und verfahren zum multidirektionalen biotransport
EP4023663A4 (de) Polypeptid und seine verwendung
EP3965796A4 (de) Verfahren und materialien zur behandlung von herz-kreislauf-erkrankungen
EP4031565A4 (de) Immuntherapieverbindungen und -verfahren
AU2020327592A1 (en) Sprayable composition and method
EP3927828A4 (de) Antikörper und enonomere
EP3957724A4 (de) Transaminase-mutant und verwendung davon
EP3933566A4 (de) Digitale vorrichtung und steuerungsverfahren dafür
EP3878953A4 (de) Monooxygenasemutant und anwendung davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210803

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40061391

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20220907

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20220901BHEP

Ipc: A61K 31/517 20060101ALI20220901BHEP

Ipc: A61K 31/519 20060101ALI20220901BHEP

Ipc: C07D 519/00 20060101ALI20220901BHEP

Ipc: C07D 239/94 20060101ALI20220901BHEP

Ipc: C07D 471/04 20060101ALI20220901BHEP

Ipc: C07D 417/14 20060101ALI20220901BHEP

Ipc: C07D 413/14 20060101ALI20220901BHEP

Ipc: C07D 405/14 20060101ALI20220901BHEP

Ipc: C07D 403/14 20060101ALI20220901BHEP

Ipc: C07D 401/14 20060101ALI20220901BHEP

Ipc: C07D 401/04 20060101AFI20220901BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031519000

Ipc: C07D0401040000

DA4 Supplementary search report drawn up and despatched (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20220929BHEP

Ipc: A61K 31/517 20060101ALI20220929BHEP

Ipc: A61K 31/519 20060101ALI20220929BHEP

Ipc: C07D 519/00 20060101ALI20220929BHEP

Ipc: C07D 239/94 20060101ALI20220929BHEP

Ipc: C07D 471/04 20060101ALI20220929BHEP

Ipc: C07D 417/14 20060101ALI20220929BHEP

Ipc: C07D 413/14 20060101ALI20220929BHEP

Ipc: C07D 405/14 20060101ALI20220929BHEP

Ipc: C07D 403/14 20060101ALI20220929BHEP

Ipc: C07D 401/14 20060101ALI20220929BHEP

Ipc: C07D 401/04 20060101AFI20220929BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20221012

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20221006BHEP

Ipc: A61K 31/517 20060101ALI20221006BHEP

Ipc: A61K 31/519 20060101ALI20221006BHEP

Ipc: C07D 519/00 20060101ALI20221006BHEP

Ipc: C07D 239/94 20060101ALI20221006BHEP

Ipc: C07D 471/04 20060101ALI20221006BHEP

Ipc: C07D 417/14 20060101ALI20221006BHEP

Ipc: C07D 413/14 20060101ALI20221006BHEP

Ipc: C07D 405/14 20060101ALI20221006BHEP

Ipc: C07D 403/14 20060101ALI20221006BHEP

Ipc: C07D 401/14 20060101ALI20221006BHEP

Ipc: C07D 401/04 20060101AFI20221006BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230925